<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02409914</url>
  </required_header>
  <id_info>
    <org_study_id>10-153</org_study_id>
    <nct_id>NCT02409914</nct_id>
  </id_info>
  <brief_title>Brain Metabolism in Polycystic Ovary Syndrome</brief_title>
  <official_title>Brain Metabolism in Women With Polycystic Ovary Syndrome: a PET/MRI Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université de Sherbrooke</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Université de Sherbrooke</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate whether higher insulin resistance in young women
      with Polycystic ovary syndrome (PCOS) is associated with reduced cerebral metabolic rate of
      glucose (CMRglu). Brain volumes using magnetic resonance imaging (MRI) and quantitative
      cerebral glucose uptake using dynamic positron emission tomography (PET) were obtained.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MRI and FDG PET scan for each participant were obtained within an average time frame of 3
      weeks. Isulin resistance were assessed with the updated homeostasis model assessment
      (HOMA2-IR).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Global Brain Glucose PET Uptake</measure>
    <time_frame>Single point in time (day 1)</time_frame>
    <description>Global brain glucose uptake was quantified using FDG with dynamic positron emission tomography.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brain MR Volumes</measure>
    <time_frame>Single point in time (day 2)</time_frame>
    <description>T1-weighted brain MR images were obtained on a 1.5 Tesla scanner. Regional volumes were determined using FreeSurfer Suite 5.0 software.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin Resistance (HOMA2-IR)</measure>
    <time_frame>Single point in time (day 1 during the FDG PET)</time_frame>
    <description>The homeostasis model assessment computational method was used to estimate insulin resistance (HOMA2-IR) from fasting plasma glucose and insulin. The HOMA2-IR is the reciprocal of insulin sensitivity (%S), as a percentage of a normal reference population (normal young adult). A higher score indicates a lower insulin sensitivity.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">7</enrollment>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>POLYCYSTIC OVARY SYNDROME (PCOS)</arm_group_label>
    <description>FDG PET scan,T1-weight MRI and blood were obtained for each participant</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Women with PCOS (n=7) were referred by physician specialist in endocrinology between March,
        2010 and September, 2013. The diagnosis of PCOS was based on clinical examination using the
        Rotterdam criteria.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of PCOS

          -  Age ≤ 35 y

          -  BMI ≤ 35

        Exclusion Criteria:

          -  Taking medications for diabetes or insulin-sensitizing drugs

          -  Drug addictions

          -  Psychiatric illness

          -  Smoking

          -  Overt evidence of heart, liver or renal disease
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>March 27, 2015</study_first_submitted>
  <study_first_submitted_qc>April 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2015</study_first_posted>
  <results_first_submitted>July 27, 2017</results_first_submitted>
  <results_first_submitted_qc>January 29, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 2, 2019</results_first_posted>
  <last_update_submitted>January 29, 2019</last_update_submitted>
  <last_update_submitted_qc>January 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Insulin Resistance</keyword>
  <keyword>Brain metabolism</keyword>
  <keyword>PET</keyword>
  <keyword>MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Women with PCOS diagnosed during a clinical examination using the Rotterdam criteria were recruited.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>POLYCYSTIC OVARY SYNDROME (PCOS)</title>
          <description>Women with PCOS. FDG PET scan,T1-weight MRI and a blood sample for the evaluation of insulin resistance were obtained within an average time frame of 3 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>POLYCYSTIC OVARY SYNDROME (PCOS)</title>
          <description>Women with PCOS diagnosed during a clinical examination using the Rotterdam criteria.
PET and MRI exams: FDG PET scan and T1-weight MRI were obtained within an average time frame of 3 weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Global Brain Glucose PET Uptake</title>
        <description>Global brain glucose uptake was quantified using FDG with dynamic positron emission tomography.</description>
        <time_frame>Single point in time (day 1)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Polycystic Ovary Syndrome (PCOS)</title>
            <description>Women with PCOS.</description>
          </group>
        </group_list>
        <measure>
          <title>Global Brain Glucose PET Uptake</title>
          <description>Global brain glucose uptake was quantified using FDG with dynamic positron emission tomography.</description>
          <units>umol/100 g/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.9" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Brain MR Volumes</title>
        <description>T1-weighted brain MR images were obtained on a 1.5 Tesla scanner. Regional volumes were determined using FreeSurfer Suite 5.0 software.</description>
        <time_frame>Single point in time (day 2)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Polycystic Ovary Syndrome (PCOS)</title>
            <description>Women with PCOS.</description>
          </group>
        </group_list>
        <measure>
          <title>Brain MR Volumes</title>
          <description>T1-weighted brain MR images were obtained on a 1.5 Tesla scanner. Regional volumes were determined using FreeSurfer Suite 5.0 software.</description>
          <units>ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Superior frontal cortex</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.6" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supramarginal cortex</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Insulin Resistance (HOMA2-IR)</title>
        <description>The homeostasis model assessment computational method was used to estimate insulin resistance (HOMA2-IR) from fasting plasma glucose and insulin. The HOMA2-IR is the reciprocal of insulin sensitivity (%S), as a percentage of a normal reference population (normal young adult). A higher score indicates a lower insulin sensitivity.</description>
        <time_frame>Single point in time (day 1 during the FDG PET)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Polycystic Ovary Syndrome (PCOS)</title>
            <description>Women with PCOS.</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Resistance (HOMA2-IR)</title>
          <description>The homeostasis model assessment computational method was used to estimate insulin resistance (HOMA2-IR) from fasting plasma glucose and insulin. The HOMA2-IR is the reciprocal of insulin sensitivity (%S), as a percentage of a normal reference population (normal young adult). A higher score indicates a lower insulin sensitivity.</description>
          <units>HOMA2-IR score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Adverse Events were not monitored/assessed</desc>
      <group_list>
        <group group_id="E1">
          <title>POLYCYSTIC OVARY SYNDROME (PCOS)</title>
          <description>Women with PCOS diagnosed during a clinical examination using the Rotterdam criteria.
PET and MRI exams: FDG PET scan and T1-weight MRI were obtained within an average time frame of 3 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Stephen Cunnane</name_or_title>
      <organization>USherbrooke</organization>
      <phone>1-819-780-2220 ext 45670</phone>
      <email>Stephen.Cunnane@USherbrooke.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

